Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in diabetic patients with hyperlipidemia (BERSON)
NCT02662569Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2016
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in hyperlipidemia and mixed dyslipidemia (4 arms), sponsored by Amgen. Primary endpoints: Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 at 12 weeks and Percent Change From Baseline in LDL-C at Week 12. Started Apr 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT02662569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662569.